Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) has received an average recommendation of “Buy” from the ten ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a buy rating and three have issued a strong buy rating on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $17.29.
Several equities analysts recently weighed in on KRRO shares. Jefferies Financial Group set a $15.00 target price on shares of Korro Bio in a report on Tuesday, October 6th. Wall Street Zen upgraded Korro Bio from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Korro Bio in a report on Tuesday, October 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Korro Bio in a research report on Friday, October 2nd.
Get Our Latest Research Report on KRRO
Insider Buying and Selling
Hedge Funds Weigh In On Korro Bio
A number of institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Korro Bio during the second quarter valued at about $10,776,000. Affinity Asset Advisors LLC acquired a new position in shares of Korro Bio in the first quarter worth about $8,002,000. Nantahala Capital Management LLC boosted its holdings in Korro Bio by 3.1% in the third quarter. Nantahala Capital Management LLC now owns 680,246 shares of the company’s stock valued at $6,741,000 after purchasing an additional 20,210 shares during the last quarter. ADAR1 Capital Management LLC purchased a new position in Korro Bio in the second quarter valued at about $7,118,000. Finally, Renaissance Technologies LLC boosted its holdings in Korro Bio by 81.9% in the first quarter. Renaissance Technologies LLC now owns 136,227 shares of the company’s stock valued at $1,542,000 after purchasing an additional 61,327 shares during the last quarter. Institutional investors and hedge funds own 13.18% of the company’s stock.
Korro Bio Stock Down 4.9%
Shares of KRRO stock traded down $0.70 on Tuesday, reaching $13.61. 78,960 shares of the stock were exchanged, compared to its average volume of 230,519. The stock has a market cap of $186.87 million, a P/E ratio of -1.50 and a beta of 3.23. The firm has a 50 day moving average of $11.86 and a two-hundred day moving average of $12.16. Korro Bio has a 1-year low of $5.20 and a 1-year high of $17.35.
Korro Bio (NASDAQ:KRRO – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.98) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.16. On average, equities research analysts predict that Korro Bio will post -4.45 EPS for the current fiscal year.
About Korro Bio
Korro Bio is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. It develops RNA-editing medicines intended to address genetic diseases by changing specific RNA sequences rather than altering a patient’s DNA. The company’s OPERA platform uses oligonucleotides to direct the body’s naturally occurring ADAR enzymes to edit targeted RNA. Korro has developed KRRO-110, an investigational candidate designed to correct a disease-associated RNA change linked to alpha-1 antitrypsin deficiency.
Featured Stories
- Five stocks we like better than Korro Bio
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.
